Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Table of Contents

Table of Contents 4th International Consensus Conference: Primary 2011 Systemic Treatment in the Management of Number 43 Operable Breast Cancer: Toward the Rapid Assessment of Therapy Efficacy Contents The Treatment of Individual Patients Is More Than a Trial, A. Bottini, A. Berruti, D. Generali, and L. Dogliotti 53 Strategies to Translate Preclinical Information to Breast Cancer Patient Benefi t, M.G. Daidone, N. Zaffaroni, and V. Cappelletti 55 The Value of Genomic Analysis of Breast Cancer in Drug Development, B. Szekely and L. Pusztai 60 Biomarkers Predicting Clinical Benefi t: Facts or Fiction? V. Guarneri, E. Barbieri, and P.F. Conte 63 Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design, 67 D. Generali, A. Berruti, C. Foroni, L. Bazzola, D. Andreis, G. Allevi, A. Bersiga, L. Dogliotti, S.B. Fox, A.L. Harris, and A. Bottini Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and 71 Gene Expression Profi les, S. Mehta, N.P. Hughes, F.M. Buffa, S.P. Li, R.F. Adams, A. Adwani, N.J. Taylor, N.C. Levitt, A.R. Padhani, A. Makris, and A.L. Harris Tissue and Soluble Biomarkers in Breast Cancer and Their Applications: Ready to Use? M. Danova, S. Delfanti, M. Manzoni, and S. Mariucci 75 kConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational Oncology, H. Thorne, G. Mitchell, and S. Fox 79 The HER2 World: Better Treatment Selection for Better Outcome, E. Tagliabue, M. Campiglio, S.M. Pupa, A. Balsari, and S. Ménard 82 The Pathologic Complete Response Open Question in Primary Therapy, C. Marchiò and A. Sapino 86 Surrogate Markers for Targeted Therapy–Based Treatment Activity and Effi cacy, G. Bianchini and L. Gianni 91 Mechanisms of Resistance to HER2 Target Therapy, G. Tortora 95 Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy for Breast Cancer, D. Generali, W.F. Symmans, 99 A. Berruti, and S.B. Fox Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging 103 for the Assessment of Changes in Tumor Biology With Treatment, S.P. Li, A.R. Padhani, and A. Makris The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer, G. Curigliano and A. Goldhirsch 108 Positron Emission Tomography and Neoadjuvant Therapy of Breast Cancer, A. Cochet, D. Generali, S.B. Fox, F. Ferrozzi, and R.J. Hicks 111 Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy, O. Metzger-Filho and E. de Azambuja 116 Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer, M. Dowsett, I. Smith, 120 J. Robertson, L. Robison, I. Pinhel, L. Johnson, J. Salter, A. Dunbier, H. Anderson, Z. Ghazoui, T. Skene, A. Evans, R. A'Hern, A. Iskender, M. Wilcox, and J. Bliss Gene Profi ling Assay and Application: The Predictive Role in Primary Therapy, D. Fumagalli, C. Desmedt, M. Ignatiadis, S. Loi, M. Piccart, 124 and C. Sotiriou New Omics Information for Clinical Trial Utility in the Primary Setting, G. Damia, M. Broggini, S. Marsoni, S. Venturini, and D. Generali 128 Bridging the Gap Between Translational Research and Clinical Application, W.R. Miller and A.A. Larionov 134 Neoadjuvant Chemotherapy: Early Response as a Guide for Further Treatment: Clinical, Radiological, and Biological, 138 M. Untch and G. von Minckwitz Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients, A. Berruti, D. Generali, V. Bertaglia, M.P. Brizzi, T. Mele, 142 L. Dogliotti, P. Bruzzi, and A. Bottini International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth 147 Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010), A. Berruti, D. Generali, M. Kaufmann, L. Puztai, G. Curigliano, M. Aglietta, L. Gianni, W.R. Miller, M. Untch, C. Sotiriou, M. Daidone, P.F. Conte, D. Kennedy, G. Damia, P. Petronini, S. Di Cosimo, P. Bruzzi, M. Dowsett, C. Desmedt, R.E. Mansel, L. Olivetti, C. Tondini, A. Sapino, P. Fenaroli, G. Tortora, H. Thorne, F. Bertolini, F. Ferrozzi, M. Danova, E. Tagliabue, E. de Azambuja, A. Makris, M. Tampellini, G. Dontu, L. Van't Veer, A.L. Harris, S.B. Fox, L. Dogliotti, and A. Bottini Erratum 152 Downloaded from https://academic.oup.com/jncimono/article-abstract/2011/43/NP/949460 by Ed 'DeepDyve' Gillespie user on 04 February 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JNCI Monographs Oxford University Press

Table of Contents

JNCI Monographs , Volume 2011 (43) – Oct 1, 2011
Download PDF
1 page

Loading next page...
 
/lp/oxford-university-press/table-of-contents-mgETd55hC0

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© The Author 2011. Published by Oxford University Press.
ISSN
1052-6773
eISSN
1745-6614
DOI
10.1093/jncimonographs/lgr045
Publisher site
See Article on Publisher Site

Abstract

4th International Consensus Conference: Primary 2011 Systemic Treatment in the Management of Number 43 Operable Breast Cancer: Toward the Rapid Assessment of Therapy Efficacy Contents The Treatment of Individual Patients Is More Than a Trial, A. Bottini, A. Berruti, D. Generali, and L. Dogliotti 53 Strategies to Translate Preclinical Information to Breast Cancer Patient Benefi t, M.G. Daidone, N. Zaffaroni, and V. Cappelletti 55 The Value of Genomic Analysis of Breast Cancer in Drug Development, B. Szekely and L. Pusztai 60 Biomarkers Predicting Clinical Benefi t: Facts or Fiction? V. Guarneri, E. Barbieri, and P.F. Conte 63 Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design, 67 D. Generali, A. Berruti, C. Foroni, L. Bazzola, D. Andreis, G. Allevi, A. Bersiga, L. Dogliotti, S.B. Fox, A.L. Harris, and A. Bottini Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and 71 Gene Expression Profi les, S. Mehta, N.P. Hughes, F.M. Buffa, S.P. Li, R.F. Adams, A. Adwani, N.J. Taylor, N.C. Levitt, A.R. Padhani, A. Makris, and A.L. Harris Tissue and Soluble Biomarkers in Breast Cancer and Their Applications: Ready to Use? M. Danova, S. Delfanti, M. Manzoni, and S. Mariucci 75 kConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational Oncology, H. Thorne, G. Mitchell, and S. Fox 79 The HER2 World: Better Treatment Selection for Better Outcome, E. Tagliabue, M. Campiglio, S.M. Pupa, A. Balsari, and S. Ménard 82 The Pathologic Complete Response Open Question in Primary Therapy, C. Marchiò and A. Sapino 86 Surrogate Markers for Targeted Therapy–Based Treatment Activity and Effi cacy, G. Bianchini and L. Gianni 91 Mechanisms of Resistance to HER2 Target Therapy, G. Tortora 95 Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy for Breast Cancer, D. Generali, W.F. Symmans, 99 A. Berruti, and S.B. Fox Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging 103 for the Assessment of Changes in Tumor Biology With Treatment, S.P. Li, A.R. Padhani, and A. Makris The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer, G. Curigliano and A. Goldhirsch 108 Positron Emission Tomography and Neoadjuvant Therapy of Breast Cancer, A. Cochet, D. Generali, S.B. Fox, F. Ferrozzi, and R.J. Hicks 111 Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy, O. Metzger-Filho and E. de Azambuja 116 Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer, M. Dowsett, I. Smith, 120 J. Robertson, L. Robison, I. Pinhel, L. Johnson, J. Salter, A. Dunbier, H. Anderson, Z. Ghazoui, T. Skene, A. Evans, R. A'Hern, A. Iskender, M. Wilcox, and J. Bliss Gene Profi ling Assay and Application: The Predictive Role in Primary Therapy, D. Fumagalli, C. Desmedt, M. Ignatiadis, S. Loi, M. Piccart, 124 and C. Sotiriou New Omics Information for Clinical Trial Utility in the Primary Setting, G. Damia, M. Broggini, S. Marsoni, S. Venturini, and D. Generali 128 Bridging the Gap Between Translational Research and Clinical Application, W.R. Miller and A.A. Larionov 134 Neoadjuvant Chemotherapy: Early Response as a Guide for Further Treatment: Clinical, Radiological, and Biological, 138 M. Untch and G. von Minckwitz Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients, A. Berruti, D. Generali, V. Bertaglia, M.P. Brizzi, T. Mele, 142 L. Dogliotti, P. Bruzzi, and A. Bottini International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth 147 Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010), A. Berruti, D. Generali, M. Kaufmann, L. Puztai, G. Curigliano, M. Aglietta, L. Gianni, W.R. Miller, M. Untch, C. Sotiriou, M. Daidone, P.F. Conte, D. Kennedy, G. Damia, P. Petronini, S. Di Cosimo, P. Bruzzi, M. Dowsett, C. Desmedt, R.E. Mansel, L. Olivetti, C. Tondini, A. Sapino, P. Fenaroli, G. Tortora, H. Thorne, F. Bertolini, F. Ferrozzi, M. Danova, E. Tagliabue, E. de Azambuja, A. Makris, M. Tampellini, G. Dontu, L. Van't Veer, A.L. Harris, S.B. Fox, L. Dogliotti, and A. Bottini Erratum 152 Downloaded from https://academic.oup.com/jncimono/article-abstract/2011/43/NP/949460 by Ed 'DeepDyve' Gillespie user on 04 February 2018

Journal

JNCI Monographs – Oxford University Press

Published: Oct 1, 2011

There are no references for this article.